Archon Biosciences logo

Archon Biosciences

archon.bio

Archon Biosciences develops geometrically tunable protein therapeutics called Antibody Cages (AbCs), which integrate antibody affinity and specificity with generative protein design to target pathways inaccessible to other technologies. Its platform uses AI-driven structural engineering to create biologics with precise control over distribution, engagement, and function for improved treatment of disease. The organization aims to solve challenging drug discovery problems by advancing new classes of biologic medicines.

Facts

HQ
Seattle, Washington, US
Sectors
Biotechnology Research
Type
Corporation Seattle business license
Employees
26
Registered name
Archon Biosciences Inc Seattle business license
Stage
Seed

Is this your organization? Claim it

UW Institute for Protein Design and Nvidia open-source RFD4-Proteina model, claims 5–10× faster designs and higher success rates

The UW Medicine Institute for Protein Design and Nvidia released RFD4-Proteina, an open-source AI model that co-designs protein sequences and atomic structures and reportedly produces candidates 5–10× faster with 5–10× higher benchmark success rates. A UW student used the model to design an improved pesticide-degrading enzyme in days, and lab tests confirmed the model's outputs behaved as expected.

UW Institute for Protein Design and Nvidia unveil RFD4-Proteina, an open-source AI model for designing functional proteins after Jensen Huang GPU grant

UW’s Institute for Protein Design and Nvidia jointly released RFD4-Proteina, an open-source AI model for designing proteins with specific functions, developed after a major GPU grant from Nvidia CEO Jensen Huang’s foundation. IPD and director David Baker say the model is faster, more efficient, and could enable new medical, sustainability, and biotechnology applications.

Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model

Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.

See all 15 stories, episodes and videos about Archon Biosciences.

People

  • George Ueda
    George Ueda Chief Technology Officer, Co-Founder
  • James Lazarovits Chief Executive Officer, Co-Founder

Online